Overview
- The study published in the Journal of Neuroscience demonstrated that the HIV envelope protein gp120 increases expression of α2δ-1 and the NMDAR subunit GluN1 and strengthens α2δ-1–GluN1 interactions in dorsal root ganglia and spinal dorsal horn.
- Functionally, gp120 raised both presynaptic and postsynaptic NMDAR activity at primary afferent to excitatory neuron synapses, producing lasting nociceptive hypersensitivity in male and female mice.
- Pharmacological treatments that block α2δ-1 interactions, including the approved drug gabapentin and a synthetic α2δ-1 C‑terminal peptide, eliminated receptor hyperactivity and reversed or reduced pain-like behaviors in the models.
- Genetic interventions that deleted Cacna2d1 or selectively removed GluN1 from dorsal root ganglion neurons significantly lessened gp120-induced hypersensitivity, confirming the pathway’s causal role.
- The findings, reported June 1, 2026, point to α2δ-1–associated NMDARs as a promising preclinical target for HIV‑associated neuropathic pain while noting that translation to human patients and clinical trials remains to be established.